Acta Chir Orthop Traumatol Cech
September 2022
PURPOSE OF THE STUDY To compare topical and intravenous (IV) administration of tranexamic acid (TXA) 2 g in patients undergoing total hip arthroplasty (THA), or total knee arthroplasty (TKA). MATERIAL AND METHODS In total, 452 patients undergoing THA or TKA were randomised to 3 groups: 1) the IV TXA group received 2 doses of TXA 1 g intravenously 3 hours apart; 2) the topical TXA group received TXA 2 g topically, and 3) the NO TXA - control group. Furthermore, each group was divided in two subgroups by performed surgery (THA versus TKA).
View Article and Find Full Text PDFDespite the effectiveness of plasma exchange (PEX) and immunosuppressants in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a number of patients still die as a result of the disease. Whether caplacizumab could rescue these patients remains still unsettled. The objective of this study was to characterise mortality patterns and prognostic factors in the first episode of aTTP.
View Article and Find Full Text PDFActa Chir Orthop Traumatol Cech
November 2020
Tranexamic acid (TXA) is widely used to limit the blood loss during total joint arthroplasty without an increased risk of thromboembolic events. We present a case of acute limb ischaemia due to thrombotic occlusion of the superficial femoral artery on the non-operated limb following a total hip arthroplasty in a 64-year-old male patient. Untreated peripheral artery disease, intravenous TXA administration, surgery, obesity and hypertension were identified as predisposing factors of the occlusion.
View Article and Find Full Text PDFBackground: Breast cancer is the main cause of cancer mortality among women. Green spaces have been recently associated with reduced cancer mortality among women. Mechanisms explaining the beneficial effect of green spaces include increased levels of physical activity and reduced exposure to air pollution, which have been both associated with cancer development.
View Article and Find Full Text PDFA safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use.
View Article and Find Full Text PDF